Analysts predict VK2735 could revolutionize the weight-loss ...

Analysts predict VK2735 could revolutionize the weight-loss market with its oral administration. Truist maintains a buy rating, praising VK2735's top-tier status. William Blair sees potential for market expansion, impressed by the drug's safety profile. Oppenheimer sees VK2735 as a potential best-in-class due to its efficacy/safety profile.